TSE:L

Loblaw Companies Ltd (L.TO)

66.47
+1.70 (2.62%)
as of Jun 24, 2026, 5:09:45 pm Market Open.
323 watching
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 15 opinions in the last 12 months.

Loblaw Companies Ltd. is Canada's leading food and drug retailer, effectively navigating challenges posed by inflation and competition. Analysts commend its strategic focus on discount formats like No Frills and the strong performance of its private labels, particularly the No Name brand. The acquisition of Shoppers Drug Mart has proven beneficial, generating robust free cash flow, and establishing a solid market position with organic growth prospects. While some experts express concerns about its current valuation being high, the company remains a reliable defensive choice in uncertain economic times. Overall, experts acknowledge its significant market share, operational efficiencies, and impressive revenue growth despite mixed sentiment regarding its valuation relative to competitors.

consensus icon
Consensus
Positive
valuation icon
Valuation
Overvalued
review icon
Similar
CST, CST
DON'T BUY
Recommended it a few years, because he thought the Shoppers Drug Mart deal would be a catalyst. But he sold his shares last year. It's hard to turn around a big company, and this has been turning for a while. They haven't found the magic formula yet and the stock has been flat.
COMMENT
Loblaw last week booted out its REIT and the stock went down, but not as much as some may think. It has strong upside potential, but has long gone sideways. Eventually, the market will get tired of this sideways movement and let it fall. The company is well-run.
DON'T BUY
His model is $61.59. A year from now this stock may be trading at the same level.
BUY

They will get involved in online shopping. There is heavy competition in this space and heavy price discounting. Loblaw is probably the best in this sector. Is a well run company. Groceries are a stable and somewhat defensive.

DON'T BUY

MRU-T vs. L-T. He has owned both in the last three years. Earnings were down 3% for MRU-T even though sales were up. L-T is facing the same problems. There are overall challenges in the whole group.

DON'T BUY

Avoid this sector. Competitive, paper-thin margins. Other sectors pay better dividends and have less volatility. Not enough of a dividend to justify holding through the sideways motion.

TOP PICK

This is a recent addition to their portfolio. Loblaw runs some dominant banners in both grocery retailing and pharmacy. Have accelerated their organic growth with the purchase of Shoppers Drugmart. They have gained market share and shown margin improvement. We like what they are doing operationally and financially. Stock is trading at 14X earnings. The value of growth and consistency in this name is exceptional. (Analysts’ price target is $76.92)

DON'T BUY

Will Shoppers Drug Mart be the top distributor of medical marijuana? He doesn't know. But the problem here with Loblaw is competition from Amazon and small indie grocers. That's why this stock has been sideways.

DON'T BUY

Long-term it looks tough for them, with serious competition from Walmart and Costco. Loblaw is trying to cut costs and enhance its digital operations. Same-store sales are sluggish, though Shoppers is doing better. More headwinds: generic drug pricing, minimum wage rises and the US exchange rate.

DON'T BUY

He owns no grocers now. Loblaw faces the Amazon threat, as well as Walmart and Costco competition. He doubts Loblaw can maintain their margins. Shoppers Drug Mart though is rock solid. Look elsewhere.

BUY

Reasonable in terms of a longer term outlook. They sell products that everyone needs: food, and pharmaceuticals and beauty products through Shoppers Drug Mart. Good positions and locations in both those segments, which are critical for those types of businesses. Experienced operators. The industry is in transition regarding goods delivery and pickup. They have click and collect, and have introduced online delivery. Some headwinds with minimum wage, which they’re now overcoming. Earnings growth not that stellar. Going forward earnings should be in mid to high single digit range. Stock is reasonably priced at around $65, with a bit of a yield.

BUY

He recently bought this. Cash flow and earnings have ticked up, though the stock has been sidways the past few years. They've done well integrating Shopper's Drug Mart. They are massively buying back stock. Also done well growing No Frills, a growth opportunity. A safe, defensive name with room to grow. Pays a 1.8% dividend.

DON'T BUY

Revenues are flat for the grocery sector. They bought back 5% of their stock and so earnings per share are going up. He would stay away from the sector because of the lack of top line growth.

PAST TOP PICK

(Past Top Pick on April 26, 2017, Down 12%) Expenses rose $100 million due to increased costs to cover higher minimum wages. Also suffered from increased competition. He sold his shares along with other food stocks. Earnings will grow 3% this year.

DON'T BUY

Lots of competition from well capitalized companies. Not really compelling form a technical point of view. Some of the reforms affecting the price of the generics drugs affect Shoppers Drug Mart that is owned by this company. There is also food inflation to deal with. Consumers staples in general is a sector that he doesn’t like. Margins are very thin.

Showing 106 to 120 of 706 entries